// App-Quantinova.ai

POS0197 (2021) : RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL

Researchers

Presenter

  • M. Boers

Principal Investigators

  • P. G. Conaghan

  • G. Schett

  • P. Mandl

  • E. Naredo

  • F. Van den Bosch

  • R. Burgos-Vargas

  • C. Gaillez

  • M. A. Dagostino

Medical Centers

  • Amsterdam UMC, Vrije Universiteit, Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

  • University of Leeds, Rheumatology, Leeds, United Kingdom

  • Medical University of Vienna, Division of Cardiology, Vienna, Austria

  • Hospital Fundación Jiménez Díaz and Autónoma University, Department of Rheumatology and Joint and Bone Research Unit, Madrid, Spain

  • Ghent University and Ghent University Hospital, Rheumatology, Ghent, Belgium

  • Hospital General de Mexico, Department of Rheumatology, Mexico City, Mexico

  • Novartis Ireland Limited, Immunology, Hepatology and Dermatology, Dublin, Ireland

  • Novartis Healthcare Private Limited, Immunology, Hepatology and Dermatology, Hyderabad, India

  • Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland

  • Catholic University of Sacred Heart, Rome, Italy, Roma, Italy

Locations

  • Netherlands

  • United Kingdom

  • Germany

  • Austria

  • Spain

  • Belgium

  • Mexico

  • Ireland

  • India

  • Switzerland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT02662985

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved